<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme) in combination with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, as first-line immunosuppressive therapy, was evaluated prospectively in a multicenter, European, phase 2 pilot study, in 35 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Results were compared with 105 age- and disease severity-matched patients from the European Blood and Marrow Transplant registry, treated with horse ATG (hATG; lymphoglobulin) and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The primary end point was response at 6 months </plain></SENT>
<SENT sid="3" pm="."><plain>At 3 months, no patients had achieved a complete response to rATG </plain></SENT>
<SENT sid="4" pm="."><plain>Partial response occurred in 11 (34%) </plain></SENT>
<SENT sid="5" pm="."><plain>At 6 months, complete response rate was 3% and partial response rate 37% </plain></SENT>
<SENT sid="6" pm="."><plain>There were 10 <z:hpo ids='HP_0011420'>deaths</z:hpo> after rATG (28.5%) and 1 after subsequent HSCT </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infections</z:e> were the main cause of <z:hpo ids='HP_0011420'>death</z:hpo> in 9 of 10 patients </plain></SENT>
<SENT sid="8" pm="."><plain>The best response rate was 60% for rATG and 67% for hATG </plain></SENT>
<SENT sid="9" pm="."><plain>For rATG, overall survival at 2 years was 68%, compared with 86% for hATG (P = .009) </plain></SENT>
<SENT sid="10" pm="."><plain>Transplant-free survival was 52% for rATG and 76% for hATG (P = .002) </plain></SENT>
<SENT sid="11" pm="."><plain>On multivariate analysis, rATG (hazard ratio = 3.9, P = .003) and age more than 37 years (hazard ratio = 4.7, P = .0008) were independent adverse risk factors for survival </plain></SENT>
<SENT sid="12" pm="."><plain>This study was registered at www.clinicaltrials.gov as NCT00471848 </plain></SENT>
</text></document>